Represented appellee Watson Pharmaceuticals, Inc. in successful defense of district court’s order dismissing Bayer’s claims of patent infringement. The Federal Circuit agreed with Watson that for a generic drug maker to infringe a method-of-use patent, the proposed label must indicate that the drug is approved (i.e., safe and effective) for the claimed method. Bayer Schering Pharma AG v. Lupin, Ltd., et al., 2012 U.S. App. LEXIS 7570, Fed. Cir. Appeal No. 2011-1143 (April 16, 2012).

Experience Center

Match our Experience to Your Needs

Experience Highlights

Outsourcing for a major credit card and check verification company
Represented a major credit card and check verification company with respect to credit card processing, call centers and back office support to two more
Insurance litigation for a construction joint venture
Represented a construction joint venture that served as the construction manager for a convention center, in a series of claims arising out of an more
Securities, M&A and Tax for James River Coal Co.
Represented James River Coal, an Appalachian coal mining company headquartered in Richmond, Virginia, in its efforts to raise capital for improving more
Patent licensing and research transactions for a medical research foundation
Represented a medical research foundation in patent licensing and sponsored research transactions since 1989.  The medical technology has spanned more